Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term ...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...

Swiss pharma giant Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause ...

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...